EGFR and malignant colon neoplasm: CHI3L1 can significantly reduce the sensitivity of cells to cetuximab and promote the proliferation of colon cancer cells by downregulating the expression of the tumor suppressor gene p53 and upregulating epidermal growth factor receptor (EGFR) expression; this suggests that CHI3L1 plays a key role in guiding individualized treatment with cetuximab [134].